Bristol-Myers Squibb

169 articles with Bristol-Myers Squibb

• CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs

  3/20/2023

  CHARM Therapeutics today announced a strategic discovery collaboration with Bristol Myers Squibb (NYSE: BMY) for the identification and optimisation of compounds against Bristol Myers Squibb selected targets.

• Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments

  3/15/2023

  Bristol Myers Squibb (NYSE: BMY) today announced meaningful progress toward its global inclusion & diversity goals and health equity commitments, meeting and exceeding some goals ahead of schedule.

• Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023

  3/9/2023

  Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2023 on Thursday, April 27, 2023.

• Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia

  3/3/2023

  Bristol Myers Squibb Receives European Commission Approval of Reblozyl ® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia.

• The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor

  3/2/2023

  Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc. today announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor XIa (FXIa) inhibitor (antithrombotic).

• Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of Cardiology

  2/27/2023

  Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research supporting the company’s cardiovascular franchise at the American College of Cardiology (ACC) Annual Scientific Session & Expo together with the World Congress of Cardiology (WCC), taking place in-person and virtually March 4-6, 2023.

• Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference

  2/3/2023

  Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023.

• Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

  2/2/2023

  Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States.

• Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022

  2/2/2023

  Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2022, which reflect robust growth of the in-line and new product portfolios, driven by strong commercial execution and continued progress of the company's pipeline.

• Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia

  1/27/2023

  Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl ® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia.

• Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

  1/27/2023

  Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis,

• Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

  1/26/2023

  Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi ® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

• Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

  1/6/2023

  Dragonfly Therapeutics, Inc. today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415.

• Bristol Myers Squibb to Present at J.P. Morgan’s 41st Annual Healthcare Conference

  1/3/2023

  Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 41st Annual Healthcare Conference on Monday, January 9, 2023.

• Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York

  1/3/2023

  Bristol Myers Squibb (NYSE: BMY ) has completed the previously announced sale of its manufacturing facility in Syracuse, New York to LOTTE BIOLOGICS.

• Envisagenics Announces Research Collaboration with Bristol Myers Squibb

  11/29/2022

  Envisagenics today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY).

• Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases

  11/21/2022

  Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across its hematology portfolio at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in New Orleans, Louisiana, and virtually, from December 10 to 13, 2022.

• Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference

  11/9/2022

  Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Wolfe Research Healthcare Conference on Wednesday, November 16, 2022 in New York City.

• Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial

  10/31/2022

  Bristol Myers Squibb (NYSE: BMY) today announced the COMMANDS study, a Phase 3, open-label, randomized trial evaluating Reblozyl.

• Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

  10/27/2022

  Obsidian Therapeutics, Inc. today announced that Bristol Myers Squibb (NYSE:BMY) has opted to extend the term of the parties' multi-year strategic collaboration for the discovery and development of novel, regulated cell therapies that utilize Obsidian's cytoDRiVE® technology for the controlled expression of the immune enhancer CD40L.